Integrated BioPharma Q3 net income $0.3M vs $16k YoY; revenue flat at $13.1M

INTEGRATED BIOPHARMA INC

2024-Q3 EPS reported -$0.01 revenue$37,571,000

Quarterly revenue $13.1M (flat YoY); operating income $0.4M vs $44k prior year.
Net income $0.3M ($0.01 diluted EPS) vs $16k ($0.00) in Q3 2023.
Nine-month revenue $37.6M (down 0.3% YoY); net loss $0.2M ($0.01 loss per share).
Two largest contract manufacturing customers represent ~90% of total revenue; management plans to expand customer base by FY2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

INTEGRATED BIOPHARMA INC reported quarter ended March 31, 2024 results: revenue $13.1 million, net income $0.3 million, EPS $0.01.

Period: quarter ended March 31, 2024
Revenue: $13.1 million
Net income: $0.3 million
EPS: $0.01
Result: reported results

Exact text from the filing

(the “Company” or “INBP”) reports its financial results for the quarter ended March 31, 2024. Revenue for each of the quarters ended March 31, 2024 and 2023 were approximately $13.1 million. The Company had operating income for the quarter ended March 31, 2024 and 2023 of approximately $0.4 million and $44,000, respectively. Revenue for the nine-month period ended

View on SEC.gov

1050 earnings releases filed in the last 30 days. Browse all earnings releases →

INTEGRATED BIOPHARMA INC filing history →

Source: SEC EDGAR

accession 0001437749-24-016041

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.